The new face of fighting cancer
The battle against cancer has raged for decades and the end game is nearing. Merus’ innovative bispecific antibody therapeutics referred to as Biclonics® are designed to recruit the immune system to kill cancer cells and tip the balance in favor of patients thanks to more effective treatments that have fewer side effects. Ultimately, it is Merus’ goal to help declare victory for patients with this devastating disease and help them lead normal lives.
Read more
Human Biclonics®
Biclonics® are designed to have several of the same features of antibodies that are produced naturally by the immune system and retain their favorable attributes including stability, predictability during manufacturing, long half-life and low immunogenicity during treatment of patients.
Read more